Lacosamide Pain UCB Pharma: Withdrawal of the marketing authorisation application



On 25 September 2008, UCB Pharma S.A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for a marketing authorisation for Lacosamide Pain UCB Pharma, for the treatment of diabetic neuropathic pain in adults.

  • List item

    Questions and answers on the withdrawal of the marketing application for Lacosamide Pain UCB Pharma (PDF/43.79 KB)

    First published: 04/11/2008
    Last updated: 04/11/2008

  • Key facts

    Lacosamide Pain UCB Pharma
    Product number
    International non-proprietary name (INN) or common name
    • lacosamide
    Active substance
    • lacosamide
    Date of withdrawal
    Company making the application
    UCB Pharma S.A.
    Withdrawal type
    Initial authorisation

    All documents

    Related information on withdrawals

    A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

    An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

    How useful was this page?

    Add your rating